Navigation Links
Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
Date:10/17/2007

Dose-related effect of sapropterin dihydrochloride

(sapropterin) on blood phenylalanine (Phe) in patients with

phenylketonuria (PKU) (Wasserstein)

-- 1495 -- Clinical Characteristics of MPS I patients in the MPS I

Registry (Bodamer)

-- 2241 -- Urinary GAG behavior and clinical correlation in three patients

with MPS I-Scheie during irregular ERT (Munoz-Rojas)

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Kuvan(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease. Both products are being developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Naglazyme(R) is a registered trademark of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Contact:

Investors Media

Eugenia Shen Susan Berg

BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.

(415) 506-6570
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Wisconsin Assembly passes capital investment bill, revised CAPCO program not presented
2. NameProtect releases annual list of top trademarkers
3. Doyle says new contracts saving state more than $16 million annually
4. Department of Commerce offers up to $1 million annually to aid tech entrepreneurs
5. Annual Bioethics Forum to explore genetic testing
6. Annual Conference Honors Tech Grant Winners
7. AG accuses BioCATT of violating meetings law
8. VC trends, company progress discussed at Mason Wells portfolio meeting
9. Beware the Dreaded Off-Site Technology Meeting
10. A disgusting video: U.S. companies sell out Americans
11. Northwestern Mutual, American Family make Computerworlds best IT workplaces

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... , NEW YORK, Dec. 4 Stemline T...re-clinical studies of its IL-3R targeting agents,...models of human chronic myeloid leukemia (CML) hav...oming 51st Annual Meeting of the American Society ...m December 5-8, 2009. The poster will be presented...
(Date:12/3/2009)..., MELVILLE, N.Y., Dec. 3 Nikon ...ruments, announced today that it has signed a lice...ikon the rights to use the Stochastic Optical Reco...e terms of the agreement, Nikon will manufacture S...th the N-STORM name. ,, Nikon Corporation Pres...
(Date:12/3/2009)..., PHILADELPHIA, Dec. 3 /PRNewswire-FirstCall/ -...l specialty biopharmaceutical company, today annou... market withdrawal of one lot of the Attention-Def...® . Shire is taking this action because some ...not meet their release liner removal specification...
(Date:12/3/2009)... , HOPKINTON, Mass., Dec. 3 /PRNewswire-FirstCa...), a leading provider of tools and services for dr...roduced Living Image 4.0 software for IVIS® i...es the more than 800 Caliper IVIS systems currentl...e 4.0 features advanced spectral unmixing tools to...
Breaking Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Caliper Life Sciences Launches Living Image(R) 4.0 Software 2
... The West Michigan Science,& Technology Initiativ...on,and financing of a new medical device company, ...t the West Michigan Science & Technology offices i...r for Health Sciences. The,company will work to de...,and implants. Other participants in the financing...
... 10 In a,presentation yesterday at the American H...sts from deCODE genetics (Nasdaq: DCGN ) presented...tiple populations that,underscore the clinical uti...iagnosis and treatment of atrial fibrillation as a...ased reference laboratory test that detects,two si...
...wswire-FirstCall/ - Diagnostic Imaging,Internation...mpany has,entered a purchase agreement to acquire ...alizes in Teleradiology, the remote readings of MR...ospitals in remote areas to,provide radiology serv...,large population centers, CTS can assist with the...
Other Biology Technology:West Michigan's Newest Medical Device Company Receives Support from the West Michigan Science & Technology Initiative and EDF Ventures 2deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke 2deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke 3deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke 4deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke 5Diagnostic Imaging - Enters Purchase Agreement to Acquire Teleradiology Company 2
(Date:12/4/2009)... , This release is available in German . , ...y of Ageing could help to understand the positive ...revious evidence from different organisms (fruit f... increases longevity, but with a potential negativ...le fruit fly reproduces less frequently with a red...
(Date:12/3/2009)... , , Our ability to learn new information and ada... to retain lifelong memories, appears to lie in th...according to a new study by NYU Langone Medicine C...his week in the journal Nature . , The scienti... of physiology and neuroscience at NYU School of M...
(Date:12/3/2009)... , , ALBUQUERQUE, N.M. Most scientists believe t...cells that signal each other to emit toxins. The s...many bacteria must be present to start the process...rmined that the very first stage of staph infectio...ent form, occurs in a single cell and that this in...
Breaking Biology News(10 mins):How nutrition affects healthy aging 2Lifelong memories linked to stable nerve connections 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Its Official Work is Bad for Our Health 21 62105 1Its Official Work is Bad for Our Health 21 62105 2Richmond Virginia Plastic Surgeon Launches State of the Art Breast Surgery Website 62102 1Richmond Virginia Plastic Surgeon Launches State of the Art Breast Surgery Website 62102 2Richmond Virginia Plastic Surgeon Launches State of the Art Breast Surgery Website 62102 3Richmond Virginia Plastic Surgeon Launches State of the Art Breast Surgery Website 62102 4Salud 21 The Oregon Pinot Noir Auction Raises Over 24607 000 62097 1Salud 21 The Oregon Pinot Noir Auction Raises Over 24607 000 62097 2Salud 21 The Oregon Pinot Noir Auction Raises Over 24607 000 62097 3
...to a rare disease plays a critical role in the bod...k down, new evidence reported in the May Cell Meta...sm underlying healthy fat metabolism and explain w...arin-Dorfman Syndrome (CDS), who carry a mutant ve...dup of fat in tissues throughout their bodies. , T...
...l of Philadelphia is launching an ambitious progra...ldhood diseases. Making use of advanced automated ..., Inc., the Hospital,s new Center for Applied Geno...s for genotyping--the process of detecting gene va...ar illnesses. , The program will focus on some of ...
...of drugs to targeted cells through the design of s...egrated Building Blocks) has won a prestigious sci...stry at the Hebrew University of Jerusalem , Jerus...ng the Kaye Innovation Award on June 13, during th...overnors. , Qvit has shown through his research...
Other Biology News:Gene linked to rare disease activates fat breakdown 2Large-scale genomics project will hunt genes behind common childhood diseases 2Large-scale genomics project will hunt genes behind common childhood diseases 3
Tube-O-DIALYZER Floats, Floats, Small from CHEMICON
Anti-Ezrin / Radixin / Moesin Antibody, Unconjugated from Cell Signaling Technology
Anti-Ezrin / Radixin / Moesin Antibody, Unconjugated from CHEMICON
Rat Anti-Mouse ABCA1 Monoclonal Antibody, Unconjugated, Clone 5A1-1422.11 from ABR-Affinity BioReagents
Biology Products: